The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical

Carolyn Bertozzi focused on bioorthogonal chemistry in 1996 and won the Nobel Prize in 2022

This is how her discovery got to cancer clinical trials

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

In 1996, Carolyn Bertozzi and her lab at UC Berkeley were working to develop a way to image cell-surface glycans: sugar-based macromolecules that coat the surface of cells. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Jacquelyn Cobb
Managing Editor
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Intismeran autogene + Keytruda improves RFS and DMFS in melanoma patients, phase III INTerpath-001 trial finds

Intismeran autogene (intismeran; V940 or mRNA-4157), a novel investigational mRNA-based individualized neoantigen therapy, plus Keytruda (pembrolizumab) improved recurrence-free survival and distant metastasis-free survival as an adjuvant treatment for patients with completely resected stage 2B-4 melanoma, according to results of the phase III INTerpath-001 trial. 
Clinical Roundup

Daraxonrasib improves OS across metastatic pancreatic cancer subgroups, phase III RASolute 302 trial finds

Rasonque (daraxonrasib) consistently provided an overall survival benefit compared with chemotherapy across all evaluated RAS genotype subgroups among patients with previously treated metastatic pancreatic adenocarcinoma, including those with no identified tumor RAS mutation, according to exploratory subgroup analyses from the phase III RASolute 302 trial.
Clinical Roundup

Camupepimut demonstrated favorable treatment effect trends in pancreatic cancer, phase II AMPLIFY-7P study finds

Camupepimut (ELI-002 7P) demonstrated consistent and favorable treatment-effect trends in patients with and without detectable baseline ctDNA and in patients without prior radiation across multiple pre-specified analyses, according to the results of a randomized phase II study of patients with resected pancreatic ductal adenocarcinoma called AMPLIFY-7P. 
Byline
Jacquelyn Cobb
Managing Editor
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account